This is a new blank check company led by Eric Grubman, the NFL’s former executive vice president/business ventures, and John Collins, the NHL’s former COO. We intend to focus on the sports and entertainment sectors as well as the technology and services that are associated with these verticals. Examples of these technology/service areas include media, […]

We intend to focus our investment efforts broadly across the entire health care industry, which encompasses among other things technology-enabled services, biopharmaceuticals, pharmaceutical value chain, medical devices, diagnostics, providers, digital health and consumer health. We will seek to capitalize on the more than 50 years of combined investing experience of our founders, James C. Momtazee and Maria […]

Headquartered in Hong Kong, we manufacture and sell high quality mechanical locksets to customers in the United States (US) and Canada. We have continued to diversify and refine our product offerings over the past 30 years to meet our customers’ needs. We believe we are one of the pioneers of mechanical lockset manufacturing in China. […]

  We are a prominent private primary and secondary education service provider in Lishui City, Zhejiang Province. According to the Frost & Sullivan report, we were one of the top 10 private primary and secondary education institutes in Zhejiang Province in terms of the students enrolled on a monthly average basis for the 2019/2020 school year. […]

We are a development-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases (cancer, neuromuscular disease and infectious diseases) with high unmet medical need. Exosomes are intercellular transfer mechanisms; they have emerged in recent years as […]

We are a biopharmaceutical company using our proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Our primary focus is oncology (cancer) but our technology may also have applications in the discovery of new therapeutics for infectious diseases, including COVID-19. Our […]

We intend to focus on opportunities in the technology sector, particularly companies pursuing a Software as a Service, or SaaS, model. Software companies will continue to benefit in the shift of more companies toward a remote workforce or a more distributed workforce, which is happening due in large part to the COVID-19 pandemic. With a $300 […]

We intend to focus our search for prospects within the insurance industry, including insurance tech (InsurTech) companies and  traditional insurance or insurance services companies.

  We are a clinical-stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients. Using our two distinct proprietary platforms, we are developing a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors.  […]

We intend to focus our search for a suitable initial business combination target in the next-generation mobility, transportation and sustainable industrial technology sectors, but we may pursue an initial business combination target in any stage of its corporate evolution or in any industry, sector or geographic location. Barry Engle, our chief executive officer, and Sam […]